Endologix Files Form 10-K; Nellix Purchase Price Allocation Finalized
IRVINE, Calif. (March 16, 2011) - Endologix, Inc. (NASDAQ: ELGX), developer of minimally invasive treatments for aortic disorders, today announced the filing of its annual report on Form 10-K and certain revisions to its previously reported unaudited fourth quarter and full year 2010 financial results.
Upon finalization of the purchase price allocation related to Endologix's December 2010 acquisition of Nellix, Inc., the Company revised the amount of the purchase price allocated to in-process research and development (IPR&D) to $40.1 million and goodwill to $22.4 million. Accordingly, the Company revised the associated deferred tax liability and the corresponding change in valuation allowance effect. This resulted in an income tax benefit of $15.1 million compared to $11.3 million previously reported. The revisions had no effect on cash flows or cash balances.
As a result, Endologix reported revised GAAP net earnings for the fourth quarter of 2010 of $11.7 million, or $0.22 per diluted share from the previously reported $8.0 million or $0.15 per diluted share; and GAAP net earnings for the full year 2010 of $10.7 million or $0.21 per fully diluted share from the previously reported $6.9 million or $0.14 per diluted share.
There were no other changes to Endologix's previously reported unaudited fourth quarter and full-year 2010 financial results, its previously reported adjusted (non-GAAP) results, or its previously reported financial guidance.
Nellix Acquisition: Purchase Price Allocation
Deferred tax liability
Other net assets
Net assets acquired
Fair value of consideration given
Less: Net assets acquired
The following information was filed by Endologix Inc (ELGX) on Wednesday, March 16, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Endologix Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed, and by Endologix Inc.
Ticker: ELGX CIK: 1013606 Form Type:10-K Annual Report Accession Number: 0001445305-11-000433 Submitted to the SEC: Wed Mar 16 2011 4:22:22 PM EST Accepted by the SEC: Wed Mar 16 2011 Period: Friday, December 31, 2010 Industry: Surgical And Medical Instruments And Apparatus